A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer

A Phase 2 Randomized Open-Label Study of Ramucirumab (IMC 1121b; RAM) in Combination with Platinum-Based Chemotherapy in Patients (PTS) with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): Results From Non-Squamous (NSQ) PTS (NCT01160744)

Annals of Oncology ◽

10.1016/s0923-7534(20)33839-4 ◽

2012 ◽

Vol 23 ◽

pp. ix408 ◽

Author(s):

R. Doebele ◽

D. Spigel ◽

M. Tehfe ◽

S. Thomas ◽

M. Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Based Chemotherapy

Second-line erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): Results from a large, open-label study

10.1200/jco.2008.26.15_suppl.19002 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 19002-19002

Author(s):

L. Crinò ◽

M. Boyer ◽

W. E. Eberhardt ◽

Z. Balikó ◽

E. F. Smit

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy

10.1200/jco.2008.26.15_suppl.8025 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8025-8025 ◽

Cited By ~ 8

Author(s):

D. Lee ◽

S. Kim ◽

K. Park ◽

J. Kim ◽

J. Lee ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Based Chemotherapy

Randomized, open-label study of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) of nonsquamous histology.

10.1200/jco.2010.28.15_suppl.tps290 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS290-TPS290 ◽

Author(s):

R. Zinner ◽

S. Saxman ◽

G. Peng ◽

W. F. Ortuzar

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).

10.1200/jco.2016.34.15_suppl.9045 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9045-9045 ◽

Cited By ~ 3

Author(s):

Jonathan Wade Goldman ◽

Jean-Charles Soria ◽

Heather A. Wakelee ◽

D. Ross Camidge ◽

Shirish M. Gadgeel ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdy483.001 ◽

2018 ◽

Vol 29 ◽

pp. ix174 ◽

Author(s):

C. Zhou ◽

Y. Lu ◽

S.-W. Kim ◽

T. Reungwetwattana ◽

J. Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Asian Patients ◽

Treatment Naïve

An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdx386.009 ◽

2017 ◽

Vol 28 ◽

pp. v542 ◽

Author(s):

I. Okamoto ◽

H. Udagawa ◽

S. Kanda ◽

T.H. Han ◽

I. Lakatos ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Abstract CT267: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV non-small cell lung cancer

10.1158/1538-7445.am2020-ct267 ◽

2020 ◽

Author(s):

Fabrice Barlesi ◽

Sandrine Hiret ◽

Christian Rolfo ◽

Italia Grenga ◽

Andre Köenig ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Phase 1B

Biomarker analyses from an open-label study of erlotinib in advanced non-small-cell lung cancer (NSCLC)

10.1200/jco.2008.26.15_suppl.19012 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 19012-19012

Author(s):

N. van Zandwijk ◽

W. Su ◽

R. Rooneem ◽

B. Mehi|Dc ◽

F. A. Franke

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in subjects with advanced non–small cell lung cancer.

10.1200/jco.2014.32.15_suppl.e19137 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e19137-e19137 ◽

Cited By ~ 3

Author(s):

Mary Colleen Pinder ◽

Naiyer A. Rizvi ◽

Sarah B. Goldberg ◽

Ani Sarkis Balmanoukian ◽

Rajesh Narwal ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Phase 1B